A woman with ovarian cancer has become the first to get an AI-designed CAR T cell therapy that targets solid tumors. This new treatment, called GB-5267, comes from a partnership between Roswell Park Comprehensive Cancer Center and Generate Biomedicines. It’s a big step for cell therapy in a cancer that often resists immune attack.
This trial does not use high-dose chemotherapy to prepare patients for treatment. There is no lymphodepletion. Patients avoid the toxic effects of chemo. That’s a major change from the usual approach to ovarian cancer, where surgery and platinum-based chemo are standard. These often fail when the cancer returns. According to an official report by Investing.com, the phase 1 trial (NCT07489287) has already dosed its first patient. The study is now recruiting people with recurrent or platinum-resistant ovarian cancer. The main goal is to check safety and tolerability.
Unlike most CAR T cell trials, this study does not require patients to undergo lymphodepleting chemotherapy before receiving the engineered cells.
How the T cells are built to fight solid tumors
GB-5267 is not a typical CAR T cell. It’s an autologous therapy armored with IL-18. AI was used to design it for three things: strong attack against MUC16-positive tumor cells, the ability to multiply, and the power to last inside the tough tumor environment. MUC16 is the target. Over 80% of ovarian tumors show this antigen. That makes it a clear target, as noted in the Investing.com clinical trial coverage.
Generate Biomedicines used AI to test many CAR designs. The focus was on how T cells work inside real tumors, not just how tightly they bind. The goal: keep the T cells active where other cell therapies have failed.
"We’re armoring the T cells with IL-18, a cytokine that will help protect them from the suppressive microenvironment of the solid tumor," said Marco Davila, MD, PhD, Senior Vice President and Associate Director for Translational Research at Roswell Park. The trial, led by Emese Zsiros, MD, PhD, FACOG, Chair of Gynecologic Oncology, gives the therapy both by IV and directly into the peritoneal cavity. This targets the main area where ovarian cancer spreads. T cells are taken from each patient, genetically changed, and grown in Roswell Park’s GMP facility. Then they are infused back into the patient.
Trial starts with a new approach
The phase 1 trial (NCT07489287) is looking for patients whose ovarian cancer has come back or did not respond to platinum chemo. Each person’s T cells are collected, engineered, and expanded at Roswell Park. Then they go back into the patient. The main aim is to see if the treatment is safe and can be tolerated. There is hope that this AI-driven, function-first method will finally make CAR T therapy work for solid tumors.
The five-year relative survival rate for ovarian cancer stands at just 51.6%, underscoring the urgent need for new therapies as recurrence and chemotherapy resistance remain major challenges.
"Recognizing a tumor antigen is only one part of the challenge. In solid tumors, a CAR T cell that kills but does not expand or persist is a partial solution," said Dinesh de Alwis, PhD, Senior Vice President and Head of Clinical Drug Development at Generate Biomedicines. The trial is built around this idea. It will test if AI-optimized T cells can keep fighting in the harsh tumor environment.
The numbers are grim. Ovarian cancer has a five-year relative survival rate of just 51.6%. When standard treatments fail, few options remain. The hope is that GB-5267, with its AI design and IL-18 armor, can bring the lasting responses that CAR T therapies have already shown in blood cancers.
What’s next for cell therapy in solid tumors?
This trial is part of a bigger push to make cell therapies work for solid tumors. CAR T cells have changed blood cancer treatment. But in solid tumors, they have struggled. The tumor microenvironment blocks immune cells. Recent reported earlier efforts have tried to expose hidden tumor antigens or change the tumor environment to help immune cells attack.
Donations to the Roswell Park Alliance Foundation’s Igniting Cancer Breakthroughs campaign and events like Ride for Roswell helped fund the research behind this trial. For more details about the phase 1 study or other trials at Roswell Park, call 1-800-ROSWELL or email ASKRoswell@RoswellPark.org.
GB-5267 is now being tested in people. The field is watching. Can AI design and cytokine armor finally make CAR T therapy work for solid tumors? If this works, it could change how ovarian cancer is treated. It might set a new standard for building and using next-generation cell therapies. Moving away from chemo and toward precision immune cells is a big shift. The clinic will show if this new path holds up.
